Acrivon Therapeutics annual shares outstanding
2021
2022
2023
2024
2025
Acrivon Therapeutics Shares Outstanding History (ACRV)
Acrivon Therapeutics reported 31.6M shares outstanding at the end of fiscal 2025.
View full Acrivon Therapeutics company overviewAcrivon Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 31.6M | 417,592 | +1.34% |
| 2024 | 2024-12-31 | 31.2M | 8.7M | +38.67% |
| 2023 | 2023-12-31 | 22.5M | 602,242 | +2.75% |
| 2022 | 2022-12-31 | 21.9M | 20.2M | +1138.75% |
| 2021 | 2021-12-31 | 1.8M | — | — |
Acrivon Therapeutics quarterly shares outstanding
Q4.21
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 42.8M | 11.4M | +36.24% |
| Q1 2026 | 2026-03-31 | 38.7M | 7.4M | +23.58% |
| Q4 2025 | 2025-12-31 | 31.6M | 417,592 | +1.34% |
| Q3 2025 | 2025-09-30 | 31.5M | 418,878 | +1.35% |
| Q2 2025 | 2025-06-30 | 31.4M | 483,489 | +1.56% |
| Q1 2025 | 2025-03-31 | 31.4M | 8.7M | +38.50% |
| Q4 2024 | 2024-12-31 | 31.2M | 8.7M | +38.67% |
| Q3 2024 | 2024-09-30 | 31.1M | 9.0M | +40.84% |
| Q2 2024 | 2024-06-30 | 31.0M | 8.9M | +40.32% |
| Q1 2024 | 2024-03-31 | 22.6M | 716,905 | +3.27% |
| Q4 2023 | 2023-12-31 | 22.5M | 602,242 | +2.75% |
| Q3 2023 | 2023-09-30 | 22.1M | 21.4M | +2933.80% |
| Q2 2023 | 2023-06-30 | 22.1M | 20.3M | +1147.13% |
| Q1 2023 | 2023-03-31 | 21.9M | — | — |
| Q4 2022 | 2022-12-31 | 21.9M | — | — |
| Q3 2022 | 2022-09-30 | 728,607.6 | — | — |
| Q4 2021 | 2021-12-31 | 1.8M | — | — |
Acrivon Therapeutics shares outstanding trends
Across the available reported history, Acrivon Therapeutics's shares outstanding moved from 31.2M to 31.6M, a change of 417,592. The latest reported quarter, Q2 2026, shows 42.8M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acrivon Therapeutics filings at SEC.gov ↗